WELCOME

Welcome to the STAMPEDE website.

We will be adding regular updates about the trial and have made all of the trial documentation available for you to download. Please check the site regularly and add us to your favourites!

ABOUT STAMPEDE

Prostate cancer accounts for around one fifth of all male cancers. In the UK there are around 25,000 new cases each year and around 10,000 deaths. Most men with prostate cancer are given hormone therapy and this is often effective for a short time at stopping the tumour growing. However in most cases over time the tumour will start to grow again.

The aim of this trial is to try to prevent the tumour re-growth by adding other treatment to the hormone therapy. The trial is currently assessing abiraterone and enzalutamide in combination with hormone therapy or radiotherapy (newly diagnosed metastatic patients only) in combination with hormone therapy.

NEWS & UPDATES

The survival results from the “original comparisons” have been now published on The Lancet. A copy of the Open Access paper can be viewed on the MRC CTU website and a link is provided here for your information:

The Lancet paper

http://www.sciencedirect.com/science/article/pii/S0140673615010375

A meta-analysis of the STAMPEDE results and similar trials has also been published in The Lancet Oncology

http://www.sciencedirect.com/science/article/pii/S1470204515004891

 

Two briefing papers have also been put together summarising the findings from the “original comparison” as well as the recommendations that followed. These can be found here

http://www.ctu.mrc.ac.uk/13706/13710/zoledronic_acid_prostate_cancer

http://www.ctu.mrc.ac.uk/13706/13710/docetaxel_prostate_cancer


Finally, two short films (15 min) have been produced aimed at patients, the public and health workers to explore and discuss the results

Results film for patients

https://vimeo.com/mrcctu/stampederesultsforpatients

Results film for health workers

https://vimeo.com/mrcctu/stampederesultsforhealthworkers

Thank you for all your support and for help making these practice-changing results available to the clinical community.

Happy reading!

Recruitment to Arm J closes on the 31st March 2016

The “enzalutamide +abiraterone comparison” has progressed through its first intermediate analysis and the second intermediate analysis is planned for March 2016. Thanks to the amazing enthusiasm and support by all participating centres, we are now fast approaching the recruitment target of approximately 1,800 patients. Current accrual rates and projections indicate that the target will be reached by the end of Q1-2016. 

For this reason, all randomisations to Arm J will stop on Thursday 31-Mar-2016 at 5pm.

Recruitment to the trial continues to the “M1/RT comparison” which looks at radiotherapy-to-the-prostate in men whose disease has already spread elsewhere. This was the second new comparison, initiated in January 2013. A forth new comparison, the “metformin comparison”, should start recruitment in April with the initiation of Arm K. More information will follow.

More than 7,900 patients from across the UK and Switzerland have joined STAMPEDE, demonstrating the feasibility and benefits of conducting new comparisons within an ongoing trial.

The STAMPEDE team would like to thank all of the site staff and patients involved in the trial.

STAMPEDE at ECCO 2015

STAMPEDE Chief Investigator, Professor Nick James, presented the updated results from the trial’s “original comparisons” at the European Cancer Congress in Vienna in September 2015.

The presentation focused on the primary outcome measure of overall survival for the pairwise comparisons of patients on arm B (standard-of-care + zoledronic acid), arm C (standard-of-care + docetaxel) and arm E (standard-of-care + zoledronic acid + docetaxel) to contemporaneously recruited patients on the control arm A (standard-of-care). The presentation also included results from a secondary analysis looking at Skeletal Events across all research comparisons

A PDF copy of the presentation can be found here. Please email mrcctu.stampede@ucl.ac.uk if you require a PPT version.

We will ensure to notify all STAMPEDE Investigators as soon as the manuscript will be published for publication.

We would be very interested to know who is downloading the presentation slides, therefore we would very much appreciate it if you can email us at mrcctu.stampede@ucl.ac.uk to let us know if you download the presentation

STAMPEDE at ASCO 2015

STAMPEDE Chief Investigator, Professor Nick James, presented the first results from the trial’s “original comparisons” at the American Society of Clinical Oncology Annual Meeting held in Chicago on 31 May 2015.

The presentation was part of the Genitourinary (Prostate) Cancer session. It focused on the primary outcome measure of overall survival for the pairwise comparisons of patients on arm B (standard-of-care + zoledronic acid), arm C (standard-of-care + docetaxel) and arm E (standard-of-care + zoledronic acid + docetaxel) to contemporaneously recruited patients on the control arm A (standard-of-care).

You can also see a more detailed news story on these findings on the main MRC CTU website.

A PDF copy of the presentation can be found here. Please email mrcctu.stampede@ucl.ac.uk if you require a PPT version.

A short summary of the results aimed for patients and trial participants can be found here. This can be used to inform patients on newly available evidence on first-line treatment of locally advanced or metastatic patients who are starting ADT for the first time.

A manuscript will be soon submitted for publication on behalf of the STAMPEDE investigators.

We would be very interested to know who is downloading the presentation slides, therefore we would very much appreciate it if you can email us at mrcctu.stampede@ucl.ac.uk to let us know if you download the presentation.

STAMPEDE: European Urology publication on M1 control patients

A new article using data from the control arm of the STAMPEDE trial has been published in European Urology. The article focuses on survival outcomes in patients with newly-diagnosed metastatic prostate cancer.

Read the European Urology article .